Skip to main content
. 2020 Jan 17;10:1571. doi: 10.3389/fphar.2019.01571

Figure 4.

Figure 4

The distribution of the assessed risk within the TOP15 medicines (A) and the high risk events related to each of the TOP15 medicines (B).